SRF — Through the Trough and Out the Other Side, One Molecule at a Time

The State of Play

SRF makes four loosely related things — refrigerant gases and specialty chemicals, plastic films for packaging, industrial textiles for tyres and conveyor belts, and a growing line of aluminium foil — and for two years (FY24 and FY25) most of those businesses were having a bad time at once. By the year ended March 2026 the biggest of them, chemicals, had pulled out of its slump: full-year revenue reached ₹15,787 crore and net profit ₹1,835 crore, up 47% on the prior year, the company’s “second best performance in our history.” The market values that recovery generously — the stock trades at about 42 times earnings and 5.7 times book — while the people who own it are quietly changing: Indian institutions have spent three years buying the shares that foreign funds and ordinary retail holders have been selling.

The Company

SRF was incorporated in 1970 and has grown into a capital-heavy manufacturer that runs four reporting segments. Chemicals is the engine — split between fluorochemicals (refrigerant gases like R-32 and R-134a, plus fluoropolymers such as PTFE) and specialty chemicals (custom-synthesised molecules sold to agrochemical and, increasingly, pharmaceutical companies). Performance Films & Foil makes BOPET and BOPP plastic films for packaging and, more recently, aluminium foil. Technical Textiles makes nylon and polyester tyre-cord fabric and belting fabric. A small Others segment covers coated and laminated fabrics.

The business model is the one common to good specialty chemical companies: spend heavily and continuously on plants, then earn back the spend over years through high-margin, hard-to-replicate products. The numbers show exactly that shape — fixed assets have grown from roughly ₹3,900 crore a decade ago to ₹13,900 crore by March 2026, and the cash-flow statement records money flowing out into investment every single year. Working capital, by contrast, is run tightly, near zero days.

Promoters — the Bharat Ram family — hold a steady 50.26%, unchanged for two years. Below them, the ownership has been shifting in one direction: domestic institutions (DIIs) climbed from about 13.7% to 21.2% over three years, while foreign institutions slipped from 20% to 16.7% and the retail public from 15.7% to 11.9%. The number of individual shareholders shrank from 2.5 lakh to 1.8 lakh. In plain terms, the float is consolidating into fewer, larger, mostly Indian institutional hands.

A note on what the public data does not show, and which this chronicle therefore cannot lean on: screener’s logged-out snapshot carried no segment-wise profit split, no promoter-by-name detail, and — oddly — listed zero “pros” against four cautionary “cons” (rich valuation at 5.7x book, a sub-13% three-year return on equity, possible capitalising of interest cost, and a low dividend payout).

The Story So Far

The honest way to tell SRF’s recent story is as a single cyclical arc — down, then turning, then climbing — read mostly through three annual reports, with the two most recent earnings calls (the only quarters for which a full transcript could be recovered; see Sources) supplying the close-up on how the recovery is actually unfolding.

FY24 — the trough

The year SRF turned fifty was not the year it would have chosen for a party. The chairman’s letter strikes a braced, weather-the-storm note rather than a celebratory one, citing “geopolitical volatility and macroeconomic uncertainties.” The numbers explain the mood. Standalone revenue fell about 11%, to ₹10,787 crore, and the drop was almost entirely chemicals: that segment’s profit collapsed by roughly ₹712 crore as refrigerant prices fell and agrochemical customers worked down their inventories instead of placing new orders. Packaging films had its own separate problem — a global glut of BOPET and BOPP capacity crushed prices, and the segment’s profit more than halved, from ₹332 crore to ₹123 crore. Only technical textiles held steady.

What management did not do is instructive: it kept spending. Total assets grew even as profit shrank, with money still going into the chemicals platform. The posture was “this is a cyclical dip, build through it.”

FY25 — the turn

A year later the tone flips. The chairman writes of “a profound sense of pride and optimism” and a company that has “emerged stronger.” The proof point sits in the films segment: as the oversupply eased, Performance Films profit doubled, from ₹123 crore to ₹255 crore. Chemicals stabilised rather than surged — profit inched up — but management’s energy went into preparing the next leg: ₹700 crore earmarked for de-bottlenecking and expansion, and a third anhydrous hydrofluoric acid (AHF) plant commissioned at Dahej, the raw-material backbone for fluorochemicals. Two smaller signals of intent: the films segment was renamed “Performance Films & Foil” — a deliberate attempt to reframe a commodity-cyclical business as a higher-value one — and the credit rating was reaffirmed at AA+ by both CRISIL and India Ratings. Technical textiles, the old reliable, quietly started to soften.

FY26 — the build pays off on the top line

By the year ended March 2026 the chemicals up-cycle that FY25 anticipated was delivering. Chemicals revenue rose 16% to ₹7,726 crore (standalone), the asset base swelled by roughly ₹1,800 crore as capex peaked, and — a small balance-sheet tell — long-term debt was converted entirely to floating rate, the fixed-rate portion falling to nil. Leadership was locked in for the long build: Kartik Bharat Ram was reappointed Joint Managing Director through March 2031. The new soft spot was technical textiles, where revenue actually fell to ₹1,877 crore — the dependable anchor of FY24 had become the laggard.

(One caveat the chronicle owes the reader: the FY26 annual-report extract did not capture the chairman’s letter or the detailed profit-by-segment narrative, so the FY26 reading above is built from the segment-revenue and balance-sheet tables, not from quoted management prose.)

Q3 FY26 (call of 20 January 2026) — record fluorochemicals, struggling specialty

The two recovered earnings calls put faces and specifics on that FY26 recovery — and reveal that it was lopsided. In the December quarter, group revenue was ₹3,713 crore (up 6%), but profit jumped far faster: EBIT up 23% and net profit up 60%, to ₹433 crore. The split inside chemicals tells the real story. Fluorochemicals had “a record quarter on all counts” — refrigerant gas volumes and prices both firm, helped by China’s production quotas keeping global supply tight. Specialty chemicals, by contrast, was being squeezed:

“Irrational pricing from Chinese competitors” — Ashish Bharat Ram, Chairman & Managing Director, describing why specialty-chemical margins fell despite a better product mix.

Management was candid that the year’s original target — roughly 20% growth for the whole chemicals segment — would be missed, “for sure,” because of specialty’s pricing pressure. It promised that the March quarter would be “significantly better than Q3” for specialty, but tempered the hope: that bump would come from purchase orders deferred out of earlier quarters, not from a genuine market turn. The agrochemical sector was “still going through a tough time.” On capex, the chairman reiterated guidance of roughly ₹2,200–2,300 crore for FY27, with the bulk shifting to a large new site in Odisha, and teased a next-generation refrigerant-gas project there with details promised “at the annual call.”

Q4 FY26 (call of 6 May 2026) — the annual call delivers the roadmap

Three things stand out from the year-end call. First, the promised specialty recovery was real but modest — the CFO’s framing was that “the worst of the price destruction is behind us,” not that demand had roared back. The chemicals segment grew 16% for the full year, exactly the miss-the-20%-target outcome flagged in January, with fluorochemicals carrying the segment and specialty as the drag. Guidance for FY27 was reset to 15–20% growth.

Second, the Odisha next-generation gas project was finally spelled out, and it is the company’s big forward bet:

A revised investment of about ₹2,300 crore at Odisha over two years, building 20,000 tonnes a year of fourth-generation HFO refrigerant gas (the three products HFO-1234yf, 1234ze and 1233zd), backward-integrated into 30,000 tonnes of hydrofluoric acid — commissioning targeted for February 2028.

HFOs are the climate-friendlier refrigerants that regulators worldwide are pushing the industry toward; management called the transition “inevitable” and said its process is in-house developed and “non-infringing” on competitors’ patents. Alongside it, a small ₹88 crore debottlenecking will lift conventional HFC capacity “north of 65,000 tonnes.”

Third, the films and foil build continues but selectively: a BOPP-BOPE line starts production around July 2026, a new ₹180 crore BOPA (polyamide) line — pitched as an import-substitution first-of-its-kind in India — is due by September 2027, while a previously planned second BOPP line was “indefinitely deferred.” Management’s read on that long-suffering segment: “the industry cycle has largely bottomed out.”

A recurring thread across both calls, worth flagging because it is a genuine near-term drag rather than spin: forex. The sharp, “unprecedented” depreciation of the rupee produced mark-to-market losses on SRF’s forward hedges, and management warned in both January and May that this pain “will extend over the near term.” A weak rupee helps an exporter eventually; the hedging book just makes the journey there bumpy.

Where Things Stand

As of the latest available data, SRF is a recovery story with most of its weight resting on one leg. Fluorochemicals — refrigerant gases, soon to include the next-generation HFOs — is doing the heavy lifting, riding a tight global supply cycle that China’s quotas help sustain. Specialty chemicals is bumping along the bottom of an agrochemical down-cycle, with management cautiously calling the worst of the price destruction over. Packaging films, after two brutal years, is described as having bottomed. Technical textiles has quietly become the weakest segment. Margins have climbed back to 22% (best since the FY23 peak), interest costs are easing, and free cash flow has turned strongly positive.

The forward picture is defined by the capex roadmap: roughly ₹2,500 crore of spending guided for FY27, anchored by the ₹2,300 crore Odisha HFO programme commissioning in early 2028, plus the films and pharma-intermediate build-outs. That is a company spending hard today against a bet that the refrigerant transition and a specialty-chemical recovery both arrive on schedule. Whether they do — and whether the missed promises stay small (specialty’s “significantly better” quarter never quite materialised as a clean number) — is what the next several quarters will settle.

The Four Checks

1. Quality and moat. A good business in parts, an ordinary one in others. The moat lives almost entirely in fluorochemicals: refrigerant-gas quotas under the Montreal Protocol’s Kigali framework are awarded on baseline production in 2024–26, which means a newcomer can build a plant but cannot legally sell into the quota market from January 2028 unless it produced in those years — a regulatory wall SRF is already inside. Layer on in-house process chemistry (521 patents filed, 156 granted, a “non-infringing” HFO process developed internally) and backward integration into hydrofluoric acid, and that segment has real protection. The rest of the portfolio does not: packaging films and technical textiles are commodity businesses where Chinese capacity sets the price, and even specialty chemicals spent FY26 absorbing “irrational pricing from Chinese competitors.” Call it a strong moat around one engine bolted to two or three moat-less carriages.

2. Returns on incremental capital and runway. Moderate returns, long runway, and the cycle decides which number you see. ROCE ran 11% in FY15, peaked at 24% in FY22, collapsed to 12–13% through the FY24–FY25 trough, and has recovered to about 15% by FY26 — screener flags the three-year ROE at just 12.4%. So through a full cycle this is a ~12–15% business that touches the low twenties at the top, earned on a fixed-asset base that has grown from roughly ₹3,900 crore to ₹13,900 crore over a decade. The runway is genuinely long — ₹2,500 crore of capex guided for FY27, the ₹2,300 crore Odisha HFO programme, a 300-acre site of which HFO uses “a 5th or a 6th” — but the incremental rupee has lately gone into films and foil capacity during an oversupply, which is part of why blended returns sit where they do. Decent reinvestment economics, not exceptional ones.

3. Capital allocation for the stage. Mostly rational for a build phase, with visible discipline at the margins. Management kept investing straight through the FY24 trough rather than retrenching, retains almost everything (dividend payout has averaged 11% of profits over three years, yield 0.33%), and funds the build with moderate leverage — borrowings of ₹5,083 crore against roughly ₹14,000 crore of net worth, AA+ rated, with interest cost falling from ₹376 crore to ₹278 crore as free cash flow turned positive (₹1,265 crore FY25, ₹747 crore FY26). The deferral of a second BOPP line “indefinitely” while the ₹180 crore BOPA import-substitution bet went ahead shows project-by-project selectivity rather than blanket expansion. The quibbles: a chunk of capital keeps flowing into commodity films capacity ahead of demand, screener flags possible capitalising of interest cost, and there is no buyback history visible in the data. Reinvestment-heavy and broadly sensible — provided the chemicals projects earn what management expects.

4. Price. Demanding. As of the June 2026 snapshot, the stock trades at ₹2,742 — a market cap of ₹81,279 crore, 42.7 times earnings and 5.79 times book — against a 14.3% ROE and an FY26 EPS of ₹61.91 that is still below the FY23 peak of ₹72.95. The market is paying a high-quality-compounder multiple for a business whose through-cycle returns are middling and whose recovery, while real, leans heavily on one segment and on a refrigerant up-cycle that Chinese quotas currently sustain. For the price to be fair, the HFO bet has to commission on time in February 2028, specialty chemicals has to genuinely recover, and margins have to hold near the top of their historical range. That is a lot of things going right already in the ticket price.

Sources

• Earnings-call transcripts read: Q3 FY26 (call of 20 January 2026, recovered from BSE) and Q4 FY26 (call of 6 May 2026, recovered from SRF’s investor site). Gap to flag: SRF’s older transcripts (Q1 FY26 and back through FY22) are no longer reliably hosted — screener’s links point to company-CDN paths that now return 404, and the BSE-listed filings for those quarters were cover letters rather than the transcripts themselves. This chronicle therefore covers only the two most recent quarters in close-up and leans on the annual reports for the longer arc.
• Annual reports read (high-signal sections): FY24, FY25, FY26. The FY26 extract did not capture the chairman’s letter or the detailed profit-by-segment MD&A (those pages came through as images); FY26 figures above are from the segment-revenue and balance-sheet tables.
• Financial snapshot: screener.in (consolidated), logged-out session, fetched 2026-06-07.
• Research dump: vault/Sources/Earnings/SRF Ltd/ (_profile_digest.md, _concall_digest.md, _ar_digest.md, raw transcripts, annual-report sections, _snapshot.json, _manifest.json). Not published.